l General Information |
Product Name | GSK1292263 |
General description | GSK1292263 is a novel GPR119 agonist, showing potential for the treatment of type 2 diabetes. |
Synonym | 5-[4-[[6-(4-methylsulfonylphenyl)pyridin-3-yl]oxymethyl]piperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole |
Purity | ≥98.0%(HPLC) | CAS Number | 1032823-75-8 |
Formula | C23H28N4O4S | Molecular Weight | 456.561 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | Solid |
Solubility(25°C) | DMSO | ≥25mg/mL |
Ethanol | Insoluble |
Water | Insoluble |
l Biological Information |
Biochem/Physiol
Actions | GSK1292263 has been investigated for the treatment of DIABETES MELLITUS, TYPE 2. |
l Storage |
Storage temp. | -20°C |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
